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Intratumoral phenotypic heterogeneity has been described in many tumor types, where it can
contribute to drug resistance and disease recurrence. We analyzed ductal and neuroendo-
crine markers in pancreatic ductal adenocarcinoma, revealing heterogeneous expression of
the neuroendocrine marker Synaptophysin within ductal lesions. Higher percentages of
Cytokeratin-Synaptophysin dual positive tumor cells correlate with shortened disease-free
survival. We observe similar lineage marker heterogeneity in mouse models of pancreatic
ductal adenocarcinoma, where lineage tracing indicates that Cytokeratin-Synaptophysin dual
positive cells arise from the exocrine compartment. Mechanistically, MYC binding is enriched
at neuroendocrine genes in mouse tumor cells and loss of MYC reduces ductal-
neuroendocrine lineage heterogeneity, while deregulated MYC expression in KRAS mutant
mice increases this phenotype. Neuroendocrine marker expression is associated with che-
moresistance and reducing MYC levels decreases gemcitabine-induced neuroendocrine
marker expression and increases chemosensitivity. Altogether, we demonstrate that MYC
facilitates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma,
contributing to poor survival and chemoresistance.
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Despite focused research efforts, advanced pancreatic ductaladenocarcinoma (PDA) remains almost uniformly fataldue, in large part, to late diagnosis when few effective
treatment options are available. Unfortunately, current standard
of care chemotherapeutic agents only marginally improve survival
time for these patients1, underscoring the need for an increased
understanding of the factors responsible for therapeutic
resistance.
Cell plasticity is a key driver of intratumoral phenotypic het-
erogeneity, which is thought to contribute to drug resistance and
poor outcome in multiple tumor types2–4. Increasing evidence
suggests that tumor cells with the capacity for phenotypic plas-
ticity may enter states that allow their survival in response to
certain selective pressures within their microenvironment.
Indeed, studies indicate that drug resistance and disease recur-
rence in prostate adenocarcinoma (PCA) and non-small cell lung
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cancer (NSCLC) can involve neuroendocrine transdifferentiation
of epithelial tumor cells. For example, in response to androgen-
deprivation therapy, prostate tumor cells begin to exhibit a
neuroendocrine phenotype and express neuroendocrine markers,
such as Synaptophysin (SYP)5 and Chromogranin A6 (ChgA),
and the degree of prostate tumor cells with neuroendocrine dif-
ferentiation features correlates with tumor progression and poor
prognosis in patients7, 8. Additionally, therapeutic pressure can
drive conversion of NSCLC to high-grade small cell lung cancer
(SCLC) with neuroendocrine morphology9. Thus, the existence of
tumor cells with neuroendocrine differentiation features may be
an important mechanism contributing to aggressive disease and
therapeutic resistance. A recent publication identiﬁed a subset of
pancreatic intraepithelial neoplasia (PanIN)-associated neu-
roendocrine cells that interacted with sensory neurons to promote
PanIN progression and formation10. However, further studies are
necessary to determine whether ductal-neuroendocrine lineage
plasticity plays a role in PDA aggressiveness and therapeutic
resistance.
In prostate cancer, the N-MYC oncoprotein plays a critical role
in driving therapy refractory neuroendocrine prostate cancer
(NEPC) and N-MYC overexpression can induce both PCA and
NEPC from a common epithelial precursor11–13, 27. Further, c-
MYC, in cooperation with Pim1 kinase, can drive invasive
prostate carcinoma with neuroendocrine differentiation14. Pre-
vious studies have deﬁned a RAS-regulated signaling pathway
that activates c-MYC (MYC) by phosphorylation at Serine 62,
which increases its protein half-life and enhances MYC’s tran-
scriptional activity15–20. We have demonstrated that this post-
translationally modiﬁed MYC is highly expressed in pancreatic
cancer21. In addition, MYC expression increases upon KRAS
expression in the mouse pancreas22. As PDA is almost universally
driven by oncogenic KRAS and given MYC’s reported role in
neuroendocrine differentiation of PCA, KRAS-induced activation
of MYC may contribute to cell lineage plasticity in PDA, that
could drive a neuroendocrine differentiation phenotype.
Here, we reveal intratumoral cell lineage heterogeneity in
human PDA, where we observe Cytokeratin (CK)-positive epi-
thelial tumor cells expressing neuroendocrine markers. We report
that higher percentages of CK-SYP co-expressing cells are sig-
niﬁcantly associated with decreased disease-free survival in
patients. Tumor cells capable of expressing SYP survive passaging
through mice in patient-derived xenograft (PDX) models, sup-
porting their tumor origin. Furthermore, we observe similar
lineage marker heterogeneity in mouse models of PDA, where
in vivo lineage tracing experiments indicate the acinar origin of
ductal SYP-expressing cells. Using a novel mouse model of PDA
combining low-level deregulated MYC expression with mutant
KRAS (KMC), we ﬁnd that deregulated MYC expression
decreases survival and drives ductal-neuroendocrine lineage
plasticity, while loss of one copy of Myc in the LSL-KrasG12D;
P53R172H/+;Pdx1-Cre (KPC) mouse model suppresses ductal-
neuroendocrine cells. Further, neuroendocrine marker expression
is associated with chemoresistance in human PDA cells, and
reducing MYC expression suppresses gemcitabine-induced neu-
roendocrine marker expression and increases gemcitabine sensi-
tivity. Taken together, these studies indicate that ductal-
neuroendocrine lineage plasticity, regulated in part by MYC, is
associated with therapeutic resistance and poor outcome in PDA.
Results
Ductal-neuroendocrine lineage plasticity in human PDA. We
analyzed the expression of ductal (CK) and neuroendocrine
(SYP) markers in human PDA and observed heterogeneous
expression of the neuroendocrine marker SYP, including both
discrete SYP positive cells and CK-SYP dual positive cells (Fig. 1a
– white arrows). Similar to what has been described in PCA with
focal neuroendocrine differentiation8, we did not observe any
obvious morphological changes in the ductal-associated SYP
positive cells (Fig. 1a, b). To investigate the clinical relevance of
CK-SYP dual positive cells in PDA, we stained tumors for CK and
SYP from a cohort of surgically resected patients with R0 status
and no evidence of disease following surgery, subsequently trea-
ted with standard of care, adjuvant gemcitabine (Supplementary
Table 1). Staining was scored as less than 5% or greater than 5%
CK-SYP co-staining. We found that higher co-staining (>5%)
correlated signiﬁcantly with shortened disease-free survival
(Fig. 1c), with the high co-staining cohort recurring, on average,
297 days earlier than the low co-staining cohort (Fig. 1d). Mul-
tivariate analysis demonstrated that clinical stage, grade and age
of the patient were not confounding variables in this analysis and
thus, high CK-SYP co-staining is an independent risk factor for
poor outcomes in PDA. Similar CK-SYP staining patterns were
observed in surgically resected tumors from an additional cohort
of PDA patients where we found that 3/10 tumors analyzed
displayed greater than 5% CK-SYP co-positive cells (Supple-
mentary Table 2), although recurrence data for this cohort is not
yet complete. We also analyzed circulating tumor cells (CTCs)
from patients with PDA for neuroendocrine marker expression
and found co-staining of CK and SYP (Fig. 1e) in 4 of 5 patients
assessed with a frequency ranging from 30 to 66% (Fig. 1f). Using
a well controlled, single-cell RNA-sequencing (RNA-seq) data
set23 generated from mouse CTCs and their matched GFP-labeled
parental tumor cells, we assessed neuroendocrine gene expression
utilizing a gene signature distinguishing neuroendocrine prostate
cancer (NEPC) from prostate adenocarcinoma (PCA) (hereafter
referred to as NEPC gene signature)11. We detected a> 2-fold
enrichment in NEPC up genes vs. PCA up genes in 66% (12 out
of 18) of the CTCs analyzed compared to 20% (5 out of 20) of
single-cell counterparts from the parental tumor (Fig. 1g). Taken
together, these data suggest that the presence of tumors cells with
neuroendocrine differentiation features is correlated with poorer
survival and a shortened time to recurrence in PDA, consistent
with the presence of neuroendocrine markers and expressed
genes in CTCs and the idea that ductal-neuroendocrine lineage
plasticity may contribute to aggressive disease.
Fig. 1 Ductal-neuroendocrine plasticity is associated with decreased survival. a Ductal-neuroendocrine lineage plasticity is observed in human PDA. Human
PDA samples were stained with SYP and Pan-CK by IF. Co-staining cells are marked with white arrows. H&E from the same tumor sample are shown
below. Scale bars indicate 100 μM. b Human PDA sample was stained with SYP by IHC. Examples of ductal-associated SYP positive cells are marked with
white arrows. Scale bars indicate 100 μM. c, d Ductal-neuroendocrine lineage plasticity is associated with poor PDA patient survival. Human PDA samples
were stained for SYP and Pan-CK and the total percentage of tumor epithelium co-staining for CK-SYP across entire sections was graded as≤5% or> 5%,
and correlated with disease-free survival c and time-to-recurrence d as described in the Methods section. For c, P= 0.007, log-rank test. For d, P= 0.017,
one-tailed Mann Whitney test. e, f Ductal-neuroendocrine lineage plasticity can be detected in circulating tumor cells (CTCs) from patients with PDA.
CTCs from patients with PDA were stained for PanCK and SYP e and the number of SYP positive or CK-SYP dual positive cells was quantiﬁed for each
patient f. Scale bar indicates 25 µM. g Analysis of NEPC gene signature in mouse CTCs (red bars) and matched single parental tumor cells (black bars)
from KPC mice (GSE51372). Samples were ranked based on ratios of NEPC UP vs. PCA UP (NEPC down) gene expression as described in the Methods
section
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Neuroendocrine gene expression in poor outcome PDA sub-
type. PDA is a heterogeneous disease and recent molecular pro-
ﬁling suggests that several molecular subtypes of PDA may exist.
These include the squamous/quasi-mesenchymal, aberrantly dif-
ferentiated endocrine exocrine (ADEX), and pancreatic pro-
genitor and immunogenic, which together make up the
previously identiﬁed classical (CL) subtype, with the squamous/
quasi-mesenchymal subtype showing signiﬁcantly worse overall
survival24, 25. We asked whether the NEPC gene signature was
enriched in any of the PDA subtypes using published RNAseq
data from 96 PDA specimens24. GSEA indicated that NEPC genes
were highly enriched in the squamous/quasi-mesenchymal sub-
type compared to the other subtypes (“REST” - Fig. 2a). We
observed negative enrichment of NEPC genes in each of the other
subtypes compared to REST (Fig. 2a) and conversely, genes
upregulated in PCA vs. NEPC were de-enriched in the squamous/
quasi-mesenchymal subtype vs. all other subtypes (Supplemen-
tary Fig. 1a), suggesting that NEPC genes are associated with the
squamous tumors that show overall poor survival.
Neuroendocrine differentiation can arise from acinar cells. To
examine the origin of the dual CK + SYP + cells, we utilized
in vivo lineage tracing in KCY mice (KrasG12D;Rosa-LSL-YFP;
Ptf1a-CreER), which express KrasG12D and YFP in response to
Cre-mediated recombination. In these studies, Cre was activated
with tamoxifen at 8 weeks, when Ptf1a-driven expression is
restricted to acinar and centro-acinar cells, followed by caerulein-
induced pancreatitis to accelerate transformation. Following
acinar-to-ductal metaplasia, these mice develop PanIN and later
PDA such that ductal lesions are YFP positive26, allowing us to
assess the origin of SYP + cells during early progression. We
observed SYP-YFP dual positive cells in the ductal lesions of KCY
mice (Fig. 2b), demonstrating that these ductal-associated SYP +
cells do not arise from the endocrine compartment, but rather are
exocrine in origin. Furthermore, we analyzed PDA patient-
derived xenografts (PDXs) for SYP and CK expression. We
detected CK + SYP + cells in serial-passaged PDX tumor tissue
(up to at least 6 passages, passage 2 shown-Fig. 2c) that co-stained
with the human Ku80 protein (Supplementary Fig. 1b), indicating
that these dual positive cells in human PDA are tumor cell-
derived, since normal islets would not be expected to survive the
time it takes for PDXs to establish nor propagate in serial passage.
MYC facilitates ductal-neuroendocrine plasticity in PDA.
Several studies have demonstrated a role for MYC in cellular
plasticity, and both c-MYC and N-MYC play a functional role in
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neuroendocrine transdifferentiation of prostate cancer cells11–14,
27. Therefore, we investigated whether c-MYC contributes to
similar ductal-neuroendocrine lineage plasticity in PDA. We
stained pancreatic tumors from end stage LSL-KrasG12D;P53R172H/
+;Pdx1-Cre (KPC) and KPC Mycﬂ/+ mice for SYP and CK
(Fig. 3a). KPC Mycﬂ/+ mice have reduced PDA progression
(Supplementary Fig. 2a) and increased survival28. Compared to
KPC mice, loss of one copy of c-Myc signiﬁcantly reduced the
percentage of CK-SYP dual positive cells in ductal lesions
(Fig. 3b). We next interrogated MYC ChIP-seq data from KPC
PDA tumor cells28 and found enrichment in MYC DNA binding
peaks within 1000 bp of genes which were upregulated in the
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NEPC gene signature compared to genes upregulated in PCA
(Fig. 3c), supporting a role for MYC in regulating the ductal-
neuroendocrine lineage plasticity in PDA.
MYC DNA binding is enhanced by phosphorylation at a
conserved residue, Serine 62 (S62) and work from our lab,
and other labs, has revealed that RAS signaling induces
the phosphorylation of MYC at S62, which is increased in
PDA15, 16, 19–21, 29. Therefore, we developed a novel mouse model
of PDA driven by KRAS and low, deregulated MYC expression
and investigated the degree of intratumoral ductal-neuroendocrine
lineage heterogeneity. We crossed our ROSA-LSL-Myc mice,
which conditionally express physiological levels of MYC30, with
LSL-KrasG12D;Pdx1-Cre (KC)31 mice, to generate LSL-KrasG12D;
ROSA-LSL-Myc;Pdx1-Cre (KrasG12DROSAMyc/Myc;Pdx-Cre or
KMC) mice (Fig. 3d). In contrast to previous reports using high
levels of MYC expression driven by Pdx1-Cre;CAGtTA;TetO-
Myc32, two copies of ROSA-driven Myc expressed in the pancreas
(ROSAMyc/Myc;Pdx-Cre) alone did not induce tumor formation or
affect overall mouse survival (Fig. 3e). However, knock-in of one
copy of ROSA-LSL-Myc in combination with KrasG12D (KrasG12-
DROSAMyc/+;Pdx-Cre) signiﬁcantly reduced survival compared to
KC mice, which was further reduced by knocking in two copies of
ROSA-LSL-Myc (KrasG12DROSAMyc/Myc;Pdx-Cre) (Fig. 3e). Simi-
lar to our ﬁndings in human PDA (Fig. 1a, b), CK + SYP + cells
occurred within the ductal lesions of KMC mice (Fig. 3f) and co-
stained with insulin (Supplementary Fig. 2b). To determine
whether the number of ductal SYP + cells change during PanIN
progression or whether MYC expression altered their frequency,
we quantiﬁed the percentage of SYP + cells within ductal
structures of KC and KMC mice. While scattered SYP + cells
could be detected in KC PanIN lesions, KMC mice had
signiﬁcantly more ductal-associated SYP + cells in equivalent stage
PanIN lesions compared to KC mice and the percent of SYP +
cells increased as PanIN lesions progressed (Fig. 3g). Taken
together, these data indicate a role for MYC in promoting ductal-
neuroendocrine plasticity in PDA.
Ductal-neuroendocrine plasticity and therapeutic resistance.
We analyzed SYP expression in human PDA cell lines, which we
have previously shown exhibit elevated levels of MYC expres-
sion29, compared to non-transformed, immortalized pancreas
ductal epithelial cells (hTERT-HPNE)33. These studies revealed
that SYP mRNA (Fig. 4a – left) and SYP protein levels (Fig. 4a –
right) were highest in the poor-outcome squamous/quasi-
mesenchymal subtype relative to the classical subtype or hTERT-
HPNE cells. In prostate and lung cancer, increased neuroendo-
crine differentiation was seen in response to therapeutic pres-
sure11, 13, 34–36 suggesting that ductal-neuroendocrine lineage
plasticity in tumor cells may be an important mechanism con-
tributing to therapeutic resistance. Therefore, we examined
whether ductal-neuroendocrine lineage plasticity in PDA could
contribute to resistance to standard of care gemcitabine, con-
sistent with our observation that PDA patients with> 5% CK +
SYP + cells recurred more rapidly on gemcitabine adjuvant
therapy (Fig. 1d). In Panc1 and MiaPaca2 cell lines, which express
moderate to high levels of SYP mRNA and protein (Fig. 4a),
gemcitabine treatment was ineffective even at high doses, while
the viability of Capan1 and HPAFII cells, that express lower levels
of SYP (Fig. 4a), was signiﬁcantly decreased upon gemcitabine
treatment (Fig. 4b). However, gemcitabine did not inhibit viabi-
lity greater than ~60% in any cell line tested. Gemcitabine
treatment resulted in increased mRNA expression of the neu-
roendocrine markers SYP and SNAP25 over time in MiaPaca2,
HPAFII, and Capan1 cells (Fig. 4c). Furthermore, the percentage
of MiaPaca1 and Capan1 cells expressing SYP protein increased
upon treatment with gemcitabine (Fig. 4d), suggesting that che-
motherapeutic stress selects for a more resistant, neuroendocrine
phenotype in residual cells. Similarly, gemcitabine-treated PDX
tumors displayed a signiﬁcant increase in SYP expression com-
pared to vehicle-treated control tumors (Fig. 4e). RNA sequen-
cing data from HPAFII cells treated with gemcitabine or PBS
control supported these data, showing that additional neu-
roendocrine genes, neuronal genes, and genes involved in vesicle
transport and neurotransmitter release were upregulated upon
gemcitabine treatment (Fig. 4f). While we did not observe a
signiﬁcant upregulation of SNAP25 in the gemcitabine treated
RNA sequencing data, other SNARE-associated genes were sig-
niﬁcantly upregulated, including CPLX3 (Complexin3) and
VAMP1 (Synaptobrevin1) (Fig. 4f). We also analyzed expression
of genes previously shown to be associated with gemcitabine
resistance37, 38 (Supplementary Fig. 3a). Notably, the expression
of RRM1, RRM2 and RRM2B, reported gemcitabine-regulated
genes, remained unchanged upon gemcitabine treatment of
HPAFII cells. Additionally, while expression of the gemcitabine
transporters SLC29A1 and SLC29A3 were also unchanged, cyti-
dine deaminase (CDA), an enzyme that inactivates intracellular
gemcitabine and is often activated during gemcitabine resistance,
was increased 2-fold upon gemcitabine treatment, which could
contribute mechanistically to resistance (Supplementary Fig. 3a).
MYC regulates neuroendocrine genes and gemcitabine
response. Consistent with our observation that MYC contributes
to ductal-neuroendocrine lineage plasticity, knockdown of
c-MYC in human PDA cell lines signiﬁcantly reduced expression
of the neuroendocrine markers SYP and ChgA in MiaPaca2 and
Panc1 cells (Fig. 5a, b). In Capan1 cells, while SYP expression was
below the level of detection by Western analysis, MYC knock-
down resulted in a signiﬁcant decrease in ChgA expression
(Fig. 5c). Therefore, we next tested whether loss of MYC would
decrease gemcitabine-induced neuroendocrine marker expres-
sion, and whether this would be associated with an increased
sensitivity to gemcitabine. As expected, exposing human PDA cell
lines to gemcitabine increased SYP protein expression and MYC
knockdown reduced SYP expression (Fig. 5d). In MiaPaca2 and
Capan1 cells, the increase in SYP expression with gemcitabine
was attenuated by knocking down MYC, while in Panc1 cells,
Fig. 3 MYC facilitates ductal-neuroendocrine lineage plasticity in PDA. a KPC or KPC Mycﬂ/+ pancreatic tissues from mice with end stage disease were
stained for SYP and Pan-CK by IF. Scale bars indicate 100 μM. Examples of co-stained cells are marked with white arrows. b The percentage of CK-SYP dual
positive cells within ductal structures relative to the total number of PanCK positive cells was quantiﬁed. n= 4 mice per group. Error bars indicate standard
error of mean. *P= 0.029 one-tailed Mann Whitney test. c Interrogation of MYC ChIP-seq data from KPC tumor cells. GSEA analysis shows enrichment in
MYC DNA binding peaks within 1000 bp of genes that are upregulated in NEPC vs. PCA11. d Schematic depicting generation of the LSL-KrasG12D;LSL-ROSA-
Myc;Pdx1-Cre (KMC) mice. e Expression of deregulated MYC in combination with oncogenic KRAS in KMC mice reduces overall survival compared to KC
mice. The number of mice and median survival of each arm is shown in the legend. f KMC pancreatic tissues were stained for PanCK and SYP by IF.
Examples of CK-SYP co-stained cells are indicated with white arrows. Scale bars indicate 100 μM. g KrasG12D;Pdx1-Cre (KC) and KMC pancreatic tissues
were stained for SYP by IHC. The percentage of SYP positive cells within the ductal epithelium relative to the total number of ductal cells was quantiﬁed in
5–10 of each lesion grade per genotype. Error bars indicate standard error of mean. ***P< 0.001, two-way ANOVA
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although SYP expression was lower with siMYC, it was still
mildly increased by gemcitabine treatment. Importantly, siMYC
signiﬁcantly enhanced the sensitivity of all three PDA cell lines to
gemcitabine, correlating with decreased SYP expression with
siMYC compared to non-targeting control siRNA (Fig. 5e).
Together, these data indicate that MYC contributes to ductal-
neuroendocrine lineage plasticity of PDA, which supports
chemoresistance.
Discussion
Accumulating evidence from multiple cancer types indicates that
tumor cells display a high degree of cellular plasticity, presumably
enabling them to survive in harsh environments. Cellular plasti-
city drives intratumoral phenotypic heterogeneity, which has
recently been linked to therapeutic resistance and disease recur-
rence2–4. While the role of intratumoral phenotypic heterogeneity
in tumor biology and therapeutic response is becoming
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increasingly recognized, there is an urgent need to identify
resistance phenotypes in these heterogeneous cancers and the
molecular mechanisms underlying the emergence of these
phenotypes.
Here, we show that a subset of human PDA tumors display
neuroendocrine differentiation features, where ductal tumor cells
express neuroendocrine markers, as has been described in pros-
tate and lung cancers9, 11, 13, 27, 36. Higher percentages of tumors
cells co-expressing CK and SYP correlated with shortened
disease-free survival in patients with PDA. Further, NEPC-
associated genes are enriched in PDA tumors of the poor out-
come squamous subtype and SYP expression is highest in the
squamous/quasi-mesenchymal subtype of human PDA cell lines.
Consistent with these data, we also detected CK-SYP dual positive
CTCs from patients with PDA and ﬁnd that individual CTCs
from KPC mice upregulate the NEPC gene signature more fre-
quently than matched tumor single cells, suggesting two possi-
bilities: (1) that CK + SYP + cells are more migratory/invasive and
possess the inherent ability to extravasate into the bloodstream or
(2) that once in the bloodstream, CTCs expressing neuroendo-
crine markers are more likely to survive in the harsh environ-
ment. Further studies will be needed to distinguish between these
two possibilities.
We also report here that tumor cells capable of expressing SYP
survive passaging through mice in PDX models, suggesting that
these dual positive cells are tumor-derived, rather than hyper-
plasia of adjacent normal islet cells. While these dual lineage
positive cells may represent tumor cell phenotypic heterogeneity
that can expand or contract due to selective pressure, we con-
ﬁrmed that these cells can be derived from the exocrine com-
partment through lineage/differentiation-state plasticity using
in vivo lineage tracing in KCY mice26 with YFP induction in adult
acinar cells. In these studies, we detected YFP positive cells that
co-express SYP in ductal lesions, demonstrating that these dual
positive cells do not originate from the endocrine (islet) com-
partment. It is also worth noting that in these studies we observed
single YFP + SYP + cells within the tumor stroma (Fig. 2b). This
data is consistent with other studies demonstrating YFP + cells in
the stroma in KCY mice26 and further supports our data shown
here that circulating tumor cells are frequently CK + SYP + . We
further observed that genes involved in EMT are upregulated
upon gemcitabine treatment (Supplementary Fig. 3b). We also
found evidence of SYP + cells that co-stained with the stem
marker Nestin in human PDA samples (Supplementary Fig. 3c),
therefore it is interesting to speculate that the plasticity of these
neuroendocrine marker-positive cells is associated with stem/
progenitor capacity and future experiments are planned to more
speciﬁcally address this possibility. Indeed, endocrine and exo-
crine lineages arise from a common bi-potential progenitor in
pancreas development39 and multiple studies have demonstrated
the ability of adult exocrine cells in the normal pancreas to
transdifferentiate into insulin-producing Beta (β) cells40, 41. While
scattered neuroendocrine cells in human PDA has been repor-
ted10, 42, the degree of ductal-neuroendocrine lineage hetero-
geneity in PDA and its potential role in therapeutic resistance has
not been previously described. We view the presence of these
EMT and stem/progenitor molecular features in PDA cells with
neuroendocrine differentiation as representing an underlying
plasticity that supports their aggressive behavior and therapeutic
resistance.
Several published studies have demonstrated a necessary role
for N-MYC and c-MYC in regulating neuroendocrine transdif-
ferentiation of prostate adenocarcinoma resulting in the forma-
tion of the aggressive neuroendocrine-differentiated subtype11, 12,
14, 27. Similarly, we demonstrate here that c-MYC helps to reg-
ulate ductal-neuroendocrine plasticity of PDA, where we show
that c-MYC bound genes in PDA are enriched in genes speciﬁ-
cally upregulated in neuroendocrine-differentiated prostate can-
cer and that loss of c-MYC in mouse and human PDA cells
decreases neuroendocrine marker expression. To further study
MYC’s potential role in ductal-neuroendocrine lineage plasticity,
we utilized our KMC mice, which express pancreas-speciﬁc sub-
oncogenic levels of MYC in combination with mutant KRAS. In
these mice, low-level MYC expression alone is insufﬁcient to
drive tumor formation, however, deregulated MYC expression
accelerated mutant KRAS-induced lesion formation. We found
that the percentage of ductal-associated SYP positive cells is
increased upon expression of MYC in KMC vs. KRAS only (KC)
mice at matched PanIN stage. We also observed an increase in
this population with PanIN progression, further supporting a role
for this process in the development of aggressive disease.
Interestingly, we also found that neuroendocrine marker
expression increased in human PDA cell lines or PDX tumors
exposed to standard of care chemotherapy, suggesting that
ductal-neuroendocrine lineage plasticity may function as a
mechanism of therapeutic resistance in PDA. This ﬁnding could
help explain the rapid recurrence of patients showing over 5%
ductal-neuroendocrine lineage heterogeneity treated with adju-
vant gemcitabine. Mechanistically, knockdown of MYC decreased
the expression of neuroendocrine markers and consistent with
this, reducing MYC increased sensitivity to chemotherapy. Thus,
targeting MYC to decrease ductal-neuroendocrine lineage plas-
ticity in PDA cells may increase tumor cell response to standard-
of-care gemcitabine. While clinically targeting MYC remains an
elusive goal, progress is being made to inactivate MYC through
inhibition of BET Bromo-domain containing proteins43, 44 and
through PP2A activation leading to MYC S62 dephosphorylation
and protein destabilization45, 46.
In conclusion, we show that ductal-neuroendocrine lineage
heterogeneity in PDA contributes to poor outcome and ther-
apeutic resistance, demonstrating a role for lineage plasticity in
aggressive PDA. The MYC oncoprotein contributes to this cell
Fig. 4 Ductal-neuroendocrine plasticity contributes to gemcitabine resistance. a SYP mRNA (left panel) and SYP protein (right panel) expression in human
PDA cell lines. Fold change in SYP mRNA expression was determined by qRT-PCR (normalized to TBP) relative to the immortalized duct epithelial cell line
hTERT-HPNE (HPNE). Fold change in SYP protein expression (normalized to GAPDH) relative to HPNE was determined by Western blot. P values indicate
signiﬁcance when comparing to HPNE. Results representative of n= 3 experimental replicates. b Cells were treated with the indicated doses of gemcitabine
and measured using MTS assay. Results represent average of n= 3 experimental replicates. c Cells were treated with gemcitabine for the indicated time
points and neuroendocrine genes were assessed by qRT PCR (normalized to TBP). P values indicate signiﬁcance when comparing each single gene to the
zero hour time point. Results representative of n= 3 experimental replicates. d MiaPaca2 and Capan1 cells were treated with gemcitabine for 72 h, ﬁxed
and stained for SYP by IF. The percentage of SYP positive cells of total DAPI positive cells was quantiﬁed for triplicate wells, 3 images/well. Representative
images and quantitation from three experimental replicates are shown. Scale bars indicate 20 µM. eWestern analysis of tumor lysates from subcutaneous
(SubQ) PDX tumors treated with vehicle or gemcitabine. SYP expression relative to GAPDH was quantiﬁed for each tumor. f HPAFII cells were treated with
PBS or gemcitabine (n= 3 experimental replicates) and RNA sequencing was performed. Fold change in neuroendocrine genes, neuronal genes, and genes
involved in vesicle trafﬁcking for gemcitabine treated vs. PBS cells are shown. For all panels, error bars indicate standard deviation and *P< 0.05, **P< 0.01
Student’s two-tailed t-test
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lineage heterogeneity in PDA and combined oncogenic KRAS
and activated MYC could drive aggressive phenotypic hetero-
geneity that may allow the emergence of a chemotherapy resistant
state enriched for neuroendocrine differentiation in PDA
patients. Indeed, the poor outcome squamous subtype of PDA is
reported to have high MYC pathway activity24 and the neu-
roendocrine gene signature is enriched in this subtype. While
difﬁcult to obtain, tumor samples collected while patients are
progressing on chemotherapy would help reveal such a
mechanism.
Methods
Cell culture and siRNA transfection. Pancreatic cancer cells used in these studies
were obtained from Michel Ouellette (University of Nebraska Medical Center,
Omaha, NE) and from Joe Gray (Oregon Health and Science University, Portland,
OR) and maintained in DMEM with 10% FBS. Cell lines were tested for myco-
plasma contamination, identities were conﬁrmed by STR proﬁling and no cell lines
used were found in the database of misidentiﬁed cell lines. Transient MYC
knockdown was performed using siRNAs (25 nM) (Dharmacon, Pittsburgh, PA)
and DharmaFECT I transfection reagent according to DharmaFECT protocols.
Non-targeting siRNA (D-001206-14) was used as a control. Cells were incubated
with siRNAs for 24 h and then cells were seeded for additional experiments. For
MTS assays, cells were trypsinized, counted and 5,000 cells were plated in 96-well
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Fig. 5 MYC regulates neuroendocrine markers and gemcitabine response. a–c Loss of MYC in human PDA cell lines decreases neuroendocrine marker
expression. Cells were transfected with siRNA targeting c-MYC or non-targeting control siRNA (siNT), total protein was harvested after 72 h and assessed
by Western blot. Fold change in protein expression (relative to GAPDH) in siMYC cells normalized to siNT is shown for three independent experimental
replicates. Error bars indicate standard deviation. *P< 0.05, **P< 0.01, ***P< 0.001, Student’s two-tailed t-test. d Cells were treated with siNT or siMYC
for 24 h, then treated with PBS or gemcitabine for 72 h, and assessed by Western blot. SYP protein expression (normalized to GAPDH) is shown relative to
siNT PBS control. gem= gemcitabine. Error bars indicate standard deviation. e Cells were treated with siMYC or siNT for 24 h, and then treated with
increasing doses of gemcitabine for 72 h. MTS assay was performed. siNT and siMYC curves are shown relative to PBS control for n= 3 experimental
replicates. Error bar indicate standard deviation. *P< 0.05, **P< 0.01, two-way ANOVA
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plates and allowed to adhere overnight. Cells were treated with PBS or increasing
doses of gemcitabine (ranging from 390 nM to 100 µM) for 72 h and analyzed using
Cell Titer 96 Aqueous One Solution/MTS (#G3580, Promega, Madison, Wiscon-
sin) on the GloMax Microplate reader (Promega, Madison, Wisconsin).
For IF analysis of Synaptophysin expression after gemcitabine treatment in
pancreatic cancer cells, cells were seeded in 96-well plates, allowed to adhere
overnight, then treated with 10 μM gemcitabine × 72 h. Images were taken using
the Nikon Spinning Disk. The percent of Synaptophysin positive cells of total
DAPI-positive cells were quantitated, 3 images/well in triplicates. For all other
experiments in which cells were treated with a single dose of gemcitabine, 10 µM
gemcitabine was used.
Genetically engineered mouse models. All animal studies were conducted in
compliance with ethical regulations and were approved by OHSU IACUC (pro-
tocol number ISO00003989). The generation and characterization of the
KrasG12Dp53R172H/+Pdx-Cre47, KPC and KPC Mycﬂ/+[28] and ROSA-LSL-Myc30
mice have been previously described. The LSL-KrasG12D;Pdx1-Cre mice31 were
obtained from Dr. Kerry Campbell at Fox Chase Cancer Center. All mice were a
mixed B6/129 background, and both males and females were used. KC and KMC
pancreatic tissue were stained for Synaptophysin by IHC. The percentage of
Synaptophysin-positive cells within the ductal epithelium relative to the total
number of ductal cells was quantiﬁed in 5–10 of each lesion grade per genotype.
For in vivo lineage tracing, KrasG12D;Ptf1a-CreERT;ROSA-YFP (KCY) mice26
were treated with 5 mg tamoxifen once a day for 5 consecutive days to induce
acinar cell speciﬁc recombination. Mice were then treated with 250 μg/kg caerulein
once a day for ﬁve days to accelerate acinar cell transformation and allowed to
recover for 9 weeks. n = 10.
Patient -derived xenografts. 2 mm3 pieces of primary pancreatic tumor tissue,
resected from patients with informed written patient consent (collected in colla-
boration with the Brenden-Colson Center for Pancreatic Care, IRB approved,
IRB00003330), were coated in Matrigel and implanted subcutaneously into the
ﬂank of 6-week-old NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (passage 1).
Once tumors reached 2 cm in diameter, animals were sacriﬁced and a 2 mm3 piece
of the passage 1 tumor was then implanted as above into a second NSG mouse
(passage 2). Tumors were harvested at 2 cm in diameter and formalin ﬁxed parafﬁn
embedded for further analysis. For experiments with gemcitabine treatment, an N1
pancreatic adenocarcinoma PDX tumor was mechanically dissociated and grown
in cell culture for> 7 passages. 1 × 106 cells were injected subcutaneously into the
mouse ﬂank. Mice were randomized into arms and when average tumor volume for
each group reached 150 mm3, tumors were treated with Vehicle or gemcitabine
(100 mg/kg I.P). All mice were sacriﬁced and tumors harvested when the ﬁrst
mouse became moribund.
Human primary tumor analysis. For survival analysis, human primary tumors
from resected pancreatic ductal adenocarcinoma (from patients with informed,
written consent) were selected from our tumor bank (Brenden-Colson Center for
Pancreatic Care, IRB approved, IRB00003330). Patients were well matched for age,
gender, AJCC stage, histologic grade, perineural invasion, lymphovascular space
invasion, R0 resection status, and adjuvant treatment (Supplementary Table 1).
Patients who received neoadjuvant therapy, had M1 disease after ﬁnal pathology, or
who died without evidence of recurrence were excluded. Disease-free survival was
measured from date of resection to earliest evidence of disease recurrence. Based on
nuclear morphology and Cytokeratin staining, the total percentage of tumor epi-
thelium co-staining for Cytokeratin and Synaptophysin across entire sections were
graded as< 5% or ≥ 5%. This distinction was selected based on the fact that co-
staining cells are seen at low frequencies in normal duct epithelium. Structures
resembling islets were not included. A second cohort of patients with tumors
representing various grades was similarly stained and quantiﬁed for CK-SYP co-
staining (n = 10).
Human CTC capture and analysis. Five treatment-naive patients with biopsy-
proven pancreatic ductal adenocarcinoma were enrolled for analysis after informed
consent was obtained (UM IRB HUM00025339). Blood was collected and analyzed,
as previously described48. Brieﬂy, peripheral venous blood was obtained through
venipuncture and collected into Cell Save preservative tubes (Janssen Pharma-
ceuticals, Raritan, New Jersey). One milliliter was applied via microﬂuidic pump to
a geometrically enhanced differential immunocapture (GEDI) chip functionalized
previously with capture antibodies speciﬁc to epithelial cell adhesion molecule
(EpCAM). After application of blood, the chip was washed with running buffer and
antibodies to Cytokeratin and Synaptophysin conjugated to ﬂuorophores and
DAPI were applied to stain cells captured on the GEDI chip, as previously
described. Stained cells were counted blindly as previously described. Scale bars
indicate 100 microns.
Mouse CTC dataset analysis. First, we obtained a list of 585 upregulated and 549
downregulated genes in NEPC vs. PCA from the Beltran et al.11 and checked for
expression of these genes in the TuGMP (black bars) and matched GMP circulating
tumor cells (CTCs–red bars) from the single cell mouse RNA-Seq data from Ting
et al.23, accession number: GSE51372. For each single cell RNAseq data, we
identiﬁed expressed genes by applying a tag threshold of 100 and then calculated a
ratio of the number or these genes that were in the up vs. down in NEPC vs. PCA.
Immunoﬂuorescence. Serial parafﬁn sections were de-parafﬁnized, rehydrated,
and blocked in 3% BSA. They were then incubated with primary antibodies
overnight at 4 °C. Antibodies used were: CK8/18 (1:200, Fitzgerald, #20R-CP004,
Suffolk, England), Synaptophysin (1:100, Sigma/Cell Marque, #336R-95/clone
MRQ-40, St. Louis, MO), Insulin (1:100, Cell Signaling Technology, #4590 S,
Danvers, MA), Pan-Cytokeratin AE1/AE3 (1:200, Santa Cruz, #sc-81714, Dallas,
TX), Nestin (1:100, Abcam #22035, Cambridge, UK). Sections were then incubated
with AlexaFluor 594 or 488 secondary antibodies (1:200, Life Technologies, Grand
Island, NY) and, DAPI (1:2000) and mounted using prolong gold anti-fade reagent
(Life Technologies, Grand Island, NY).
Immunohistochemistry. Unstained sections were de-parafﬁnized, rehydrated, and
placed in Target Retrieval Solution (Dako, Carpinteria, CA) for 10 min at 100 °C.
After cooling for 20 min, slides were quenched with 3% hydrogen peroxide for 5
min, followed by blocking with 3% goat serum and primary antibody incubation
(Synaptophysin, 1:200, Sigma/Cell Marque #336R-95/clone MRQ-40, St. Louis,
MO) overnight at 4 °C. Sections were then incubated with anti-biotin secondary
antibodies (1:1000) and labeling was then detected with the Vectastain ABC kit
(Vector Laboratories). Slides were mounted using Vectamount mounting media
(Vector Laboratories).
RNA sequencing and gene set enrichment analysis . HPAFII cells were treated
for 72 h with 10 μM gemcitabine, RNA was isolated using RNeasy mini-kit (Qia-
gen) according to the manufacturer’s protocol. RNA-seq libraries were generated
using standard TruSeq reagents for analysis in the MPSSR at OHSU using an
Illumina HiSeq2500. In total 50 base pair single reads sequences were generated
and called using the standard Illumina pipeline, requiring at least 20 M reads per
library. Sequence reads were trimmed to 44 bases and aligned with the Bowtie short
read aligner version 1.0.0. We allowed 3 miss-matches, but required unique best
matches. Gene summaries were calculated based on UCSC RefSeq gene annotation
for hg19 and used for statistical analysis with DESeq2. Reads Per Kilo-base per
Million (RPKM) were calculated for use in gene set enrichment analysis (GSEA)
using the following web site: http://www.broad.mit.edu/gsea/.
For GSEA analysis to determine if NEPC upregulated genes were enriched in
human PDA subtypes, we used the 96 PDAC ICGC RNAseq dataset from Bailey
et al.24 and their designated subtypes for each sample identiﬁed, looking for
enrichment of the upregulated genes in the NEPC vs. PCA comparison from
Beltran et al.11. We used GSEA software comparing each individual subtype to the
rest.
For analysis of MYC chIP seq data in KPC tumor cells from Walz et al.28, we
selected peaks with an FDR q-value of less than or equal to 0.01, annotated them
with the 5 prime ends of Ref-Seq genes and then selected all genes with one or
more MYC ChIP peaks within 1000 bases of their 5 prime end. Next, we created a
ranked list of genes from the Beltran NEPC vs. PCA comparison and used GSEA
software to test for enrichment of the MYC ChIP genes in the NEPC vs. PCA
ranked list.
Quantitative RT-PCR. RNA was isolated using RNeasy mini-kit (Qiagen)
according to the manufacturer’s protocol. cDNA was generated using the High
Capacity cDNA Reverse Transcription kit (ABI, Foster City, California). qRT-PCR
analysis was performed using SYBR Green reagent (Invitrogen) for Synaptophysin
(SYP) and SNAP25 normalized to the internal control TATA-box binding protein
(TBP). Primers were validated by performing a standard melt curve analysis. Pri-
mer sequences are listed in Supplementary Table 3. For qRT-PCR, the cycle
numbers for each run were used to calculate fold change using the ddt(ct) method
between each sample and the average of the control sample (set as 1) in gene
expression as follows:
dt(ct) = SYP cycle # - GAPDH cycle #
ddt(ct) = dt(ct) – average dt(ct) of normal samples
Fold Change = Power(2,ddt(ct))
Western blot analysis. Cells were homogenized in ice-cold AB-MYC lysis buffer
(1 M Tris pH 7.5, 5 M NaCl, 10% Triton X-100, 10% DOC, 20% SDS, 0.5 M EDTA,
1× protease and phosphatase inhibitors (Roche, Indianapolis, Indiana)), passed
through a 30 gauge needle, and cleared by centrifugation at 4 °C, 13,000xg for 10
min. Protein concentration was determined using the DC protein assay (BioRad,
Hercules, California). Proteins were separated by SDS–PAGE and transferred to
nitrocellulose membranes. Membranes were blocked in blocking buffer (Aqua
block, 1:1 in PBS, East Coast Bio, North Berwick, Maine) for 1 h and incubated in
primary antibody in blocking buffer overnight. Membranes were then washed with
PBS-T (Phosphate-buffered saline, 0.1% Tween-20), incubated in Fluor 680 and
IRDye 800 secondary antibodies (1:10,000) for 1 h, washed with PBS-T and
visualized using the Odyssey IR imager (LI-COR, Lincoln, Nebraska) that can
detect both Fluor 680 and IRDye 800 secondary antibodies. Quantiﬁcation of
Western blots was done using the Odyssey IR software, version 1.2 (LI-COR). The
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following primary antibodies were used: Synaptophysin (1:500, Sigma/Cell Marque
#336R-95/clone MRQ-40, St. Louis, MO)), MYC (1:1000, Abcam #32072, Cam-
bridge, UK), Chromogranin A (1:100, Abcam #15160, Cambridge, UK) and
GAPDH (1:10,000, Invitrogen #AM4300, Carlsbad, CA). Images of uncropped
Western blots can be found in Supplementary Fig. 4.
Data and statistics. Three or more independent biological replicate experiments
were performed in all cases, except when primary patient materials were used. All
standard errors were calculated from biological replicates. Unless otherwise stated
in the ﬁgure legends, P values were calculated using a standard Student’s t test
analysis (two-tailed distribution and two-sample unequal variance) to determine
statistical signiﬁcance as indicated in the graphs. P-values for relevant comparisons
are given. If no P value is shown, the comparison is not relevant or not signiﬁcant.
To determine if CK-SYP staining is an independent risk factor for poor outcome in
PDA patients, we performed multivariate analysis to determine if clinical stage,
grade or age signiﬁcantly altered relationship between CK-SYP co-staining and
days-to-recurrence. Brieﬂy, we used R software to perform multiple linear
regression, ﬁtting the following models: (1) DaysToRecurrence ~ CoStaining (2)
DaysToRecurrence ~ CoStaining + ClinicalStage (3) DaysToRecurrence ~ CoSt-
aining + Grade (4) DaysToRecurrence ~ CoStaining + Age. These potential con-
founding variables altered the magnitude of the co-staining effect by less than 10%,
therefore we determined the effect of co-staining to be independent of these
potential confounders.
Data availability. The authors declare that all data supporting the ﬁndings of this
study are available within the paper (and its Supplementary Information ﬁles) or
will be made available upon request. Accession number for RNA-sequencing of
HPAFII cells treated with PBS or gemcitabine from this manu-
script: GSE106336. Accession number for single-cell mouse RNA-Seq data from
Ting et al.23: GSE51372.
Received: 27 April 2017 Accepted: 26 October 2017
References
1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2015. CA Cancer. J. Clin.
65, 5–29 (2015).
2. Sipos, F., Constantinovits, M. & Muzes, G. Intratumoral functional
heterogeneity and chemotherapy.World J. Gastroenterol. 20, 2429–2432 (2014).
3. Martelotto, L. G., Ng, C. K., Piscuoglio, S., Weigelt, B. & Reis-Filho, J. S. Breast
cancer intra-tumor heterogeneity. Breast Cancer Res. 16, 210 (2014).
4. Zellmer, V. R. & Zhang, S. Evolving concepts of tumor heterogeneity. Cell
Biosci. 4, 69 (2014).
5. Chejfec, G. et al. Synaptophysin. A new marker for pancreatic neuroendocrine
tumors. Am. J. Surg. Pathol. 11, 241–247 (1987).
6. Eriksson, B. et al. A polyclonal antiserum against chromogranin A and B–a new
sensitive marker for neuroendocrine tumours. Acta Endocrinol. 122, 145–155
(1990).
7. Wright, M. E., Tsai, M. J. & Aebersold, R. Androgen receptor represses the
neuroendocrine transdifferentiation process in prostate cancer cells. Mol.
Endocrinol. 17, 1726–1737 (2003).
8. Parimi, V., Goyal, R., Poropatich, K. & Yang, X. J. Neuroendocrine
differentiation of prostate cancer: a review. Am. J. Clin. Exp. Urol. 2, 273–285
(2014).
9. Popat, S. et al. Transformation to “high grade” neuroendocrine carcinoma as an
acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma.
Lung Cancer 80, 1–4 (2013).
10. Sinha, S. et al. PanIN neuroendocrine cells promote tumorigenesis via neuronal
crosstalk. Cancer Res. 77, 1868–1879 (2017).
11. Beltran, H. et al. Molecular characterization of neuroendocrine prostate cancer
and identiﬁcation of new drug targets. Cancer Discov. 1, 487–495 (2011).
12. Dardenne, E. et al. N-Myc induces an EZH2-Mediated transcriptional program
driving neuroendocrine prostate cancer. Cancer Cell 30, 563–577 (2016).
13. Beltran, H. et al. Divergent clonal evolution of castration-resistant
neuroendocrine prostate cancer. Nat. Med. 22, 298–305 (2016).
14. Wang, J. et al. Pim1 kinase synergizes with c-MYC to induce advanced prostate
carcinoma. Oncogene 29, 2477–2487 (2010).
15. Benassi, B. et al. c-Myc phosphorylation is required for cellular response to
oxidative stress. Mol. Cell 21, 509–519 (2006).
16. Sears, R. et al. Multiple Ras-dependent phosphorylation pathways regulate Myc
protein stability. Genes Dev. 14, 2501–2514 (2000).
17. Sears, R., Leone, G., DeGregori, J. & Nevins, J. R. Ras enhances Myc protein
stability. Mol. Cell 3, 169–179 (1999).
18. Lutterbach, B. & Hann, S. R. Hierarchical phosphorylation at N-terminal
transformation-sensitive sites in c-Myc protein is regulated by mitogens and in
mitosis. Mol. Cell Biol. 14, 5510–5522 (1994).
19. Arnold, H. K. et al. The Axin1 scaffold protein promotes formation of a
degradation complex for c-Myc. EMBO J. 28, 500–512 (2009).
20. Yeh, E. et al. A signalling pathway controlling c-Myc degradation that impacts
oncogenic transformation of human cells. Nat. Cell Biol. 6, 308–318 (2004).
21. Farrell, A. S. et al. Pin1 regulates the dynamics of c-Myc DNA binding to
facilitate target gene regulation and oncogenesis. Mol. Cell. Biol. 33, 2930–2949
(2013).
22. Mazur, P. K. et al. Notch2 is required for progression of pancreatic
intraepithelial neoplasia and development of pancreatic ductal
adenocarcinoma. Proc. Natl Acad. Sci. USA 107, 13438–13443 (2010).
23. Ting, D. T. et al. Single-cell RNA sequencing identiﬁes extracellular matrix gene
expression by pancreatic circulating tumor cells. Cell Rep. 8, 1905–1918 (2014).
24. Bailey, P. et al. Genomic analyses identify molecular subtypes of pancreatic
cancer. Nature 531, 47–52 (2016).
25. Collisson, E. A. et al. Subtypes of pancreatic ductal adenocarcinoma and their
differing responses to therapy. Nat. Med. 17, 500–503 (2011).
26. Rhim, A. D. et al. EMT and dissemination precede pancreatic tumor formation.
Cell 148, 349–361 (2012).
27. Lee, J. K. et al. N-Myc drives neuroendocrine prostate cancer initiated from
human prostate epithelial cells. Cancer Cell. 29, 536–547 (2016).
28. Walz, S. et al. Activation and repression by oncogenic MYC shape tumour-
speciﬁc gene expression proﬁles. Nature 511, 483–487 (2014).
29. Farrell, A. S. et al. Targeting inhibitors of the tumor suppressor PP2A for the
treatment of pancreatic cancer. Mol. Cancer Res. 12, 924–939 (2014).
30. Wang, X. et al. Phosphorylation regulates c-Myc’s oncogenic activity in the
mammary gland. Cancer Res. 71, 925–936 (2011).
31. Hingorani, S. R. et al. Preinvasive and invasive ductal pancreatic cancer and its
early detection in the mouse. Cancer Cell. 4, 437–450 (2003).
32. Lin, W. C. et al. Dormant cancer cells contribute to residual disease in a model
of reversible pancreatic cancer. Cancer Res. 73, 1821–1830 (2013).
33. Lee, K. M., Nguyen, C., Ulrich, A. B., Pour, P. M. & Ouellette, M. M.
Immortalization with telomerase of the Nestin-positive cells of the human
pancreas. Biochem. Biophys. Res. Commun. 301, 1038–1044 (2003).
34. Yuan, T. C., Veeramani, S. & Lin, M. F. Neuroendocrine-like prostate cancer
cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells.
Endocr. Relat. Cancer 14, 531–547 (2007).
35. Terry, S. et al. Cross modulation between the androgen receptor axis and
protocadherin-PC in mediating neuroendocrine transdifferentiation and
therapeutic resistance of prostate cancer. Neoplasia 15, 761–772 (2013).
36. Lim, J. U. et al. Transformation into large-cell neuroendocrine carcinoma
associated with acquired resistance to erlotinib in nonsmall cell lung cancer.
Korean J. Intern. Med. 29, 830–833 (2014).
37. Nakano, Y. et al. Gemcitabine chemoresistance and molecular markers
associated with gemcitabine transport and metabolism in human pancreatic
cancer cells. Br. J. Cancer 96, 457–463 (2007).
38. Sebastiani, V. et al. Immunohistochemical and genetic evaluation of
deoxycytidine kinase in pancreatic cancer: relationship to molecular
mechanisms of gemcitabine resistance and survival. Clin. Cancer. Res. 12,
2492–2497 (2006).
39. Shih, H. P., Wang, A. & Sander, M. Pancreas organogenesis: from lineage
determination to morphogenesis. Annu. Rev. Cell. Dev. Biol. 29, 81–105
(2013).
40. Minami, K. et al. Lineage tracing and characterization of insulin-secreting cells
generated from adult pancreatic acinar cells. Proc. Natl Acad. Sci. 102,
15116–15121 (2005).
41. Zhou, Q., Brown, J., Kanarek, A., Rajagopal, J. & Melton, D. A. In vivo
reprogramming of adult pancreatic exocrine cells to β-cells. Nature 455,
627–632 (2008).
42. Linder, S. et al. Neuroendocrine cells in pancreatic duct adenocarcinoma: an
immunohistochemical study. J. Exp. Clin. Cancer Res. 25, 213–221 (2006).
43. Delmore, J. E. et al. BET bromodomain inhibition as a therapeutic strategy to
target c-Myc. Cell 146, 904–917 (2011).
44. Mazur, P. K. et al. Combined inhibition of BET family proteins and histone
deacetylases as a potential epigenetics-based therapy for pancreatic ductal
adenocarcinoma. Nat. Med. 21, 1163–1171 (2015).
45. Janghorban, M. et al. Targeting c-MYC by antagonizing PP2A inhibitors in
breast cancer. Proc. Natl Acad. Sci. USA 111, 9157–9162 (2014).
46. Sangodkar, J. et al. Activation of tumor suppressor protein PP2A inhibits
KRAS-driven tumor growth. J. Clin. Invest. 127, 2081–2090 (2017).
47. Hingorani, S. R. et al. Trp53R172H and KrasG12D cooperate to promote
chromosomal instability and widely metastatic pancreatic ductal
adenocarcinoma in mice. Cancer Cell 7, 469–483 (2005).
48. Rhim, A. D. et al. Detection of circulating pancreas epithelial cells in patients
with pancreatic cystic lesions. Gastroenterology 146, 647–651 (2014).
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01967-6 ARTICLE
NATURE COMMUNICATIONS |8:  1728 |DOI: 10.1038/s41467-017-01967-6 |www.nature.com/naturecommunications 11
Acknowledgements
Primary pancreatic tumor tissue, resected from patients with informed written patient
consent, was supplied by the Brenden-Colson Center for Pancreatic Care (BCCPC). H&E
staining was performed by the OHSU Histopathology Shared Resource, and short read
sequencing assays (RNA-seq) were performed by the OHSU Massively Parallel Sequen-
cing Shared Resource. Multivariate statistical analysis was performed with assistance from
the OHSU Biostatistics Shared Resource. These OHSU Shared Resources are supported by
the Knight NCI Cancer Center Support Grant 5P30CA069533. We thank Dr. Joe Gray
and Dr. Michel Ouellette for providing cell lines. ASF was supported by a Collins Medical
Trust Fund Award, Knight Cancer Institute Career Development Award, and R01
CA196228. RCS was supported by R01s CA196228, CA100855 and CA129040, DOD
BC061306, and the Anna Fuller and Brenden-Colson Foundations. B.L.A-P. was sup-
ported by NRSA1F32CA192769-01. M.M.J. was supported by NRSA1F32CA213764-01.
Author contributions
A.S.F., M.M.J., B.L.A-P. and R.C.S. designed experiments and wrote the paper. S.L.M., E.
D.P., and A.D.R. performed human CTC analysis. H.C.C. and M.T.H. performed KCY
analysis. A.S.F. generated and characterized the KMC mouse model. C.L. and D.S.
performed histopathological analysis of KMC mice. B.L.A-P. and M.C.T. generated
human PDX tumors and performed analyses. L.M.H. performed bioinformatics analysis
of NEPC gene expression in PDA subtypes. C.P. performed all additional bioinformatics
analysis. J.P.M., O.J.S., N.M., D.J.M., and B.LA.-P. performed KPC Mycﬂ/+ analysis. T.S.
A. performed SYP IF on ﬁxed cells and quantiﬁcation of SYP staining. P.J.W., J.L., N.D.
K., and N.E. performed IF analysis of human PDA samples. P.J.W. and J.L. performed
patient survival analysis. M.M.J. performed and analyzed RNA sequencing, performed all
Western and qRT PCR analysis and MYC knockdown studies in PDA cells. Z.P.J. per-
formed additional experiments. All authors contributed to data analysis and read the
manuscript. R.C.S. and B.C.S. supervised the project.
Additional information
Supplementary Information accompanies this paper at doi:10.1038/s41467-017-01967-6.
Competing interests: The authors declare no competing ﬁnancial interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2017
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01967-6
12 NATURE COMMUNICATIONS | 8:  1728 |DOI: 10.1038/s41467-017-01967-6 |www.nature.com/naturecommunications
